key: cord-0735202-asy5ugnr authors: Prendki, Virginie; Tiseo, Giusy; Falcone, Marco title: Caring for older adults during the COVID-19 pandemic date: 2022-03-11 journal: Clin Microbiol Infect DOI: 10.1016/j.cmi.2022.02.040 sha: afe04c687c7e6c0cb59d6342f487831dc22ecafe doc_id: 735202 cord_uid: asy5ugnr BACKGROUND: Elderly patients represent a high-risk group with increased risk of death from COVID-19. Despite the amount of published studies, several unmet needs about the care for older adults exist. OBJECTIVES: To discuss unmet needs of COVID-19 in this special population. SOURCES: A literature review for studies on COVID-19 in elderly patients published between December 2019 and November 2021 was performed. Clinical questions were formulated to guide the literature search. The search was conducted in the MEDLINE database combining specific search terms. Two reviewers independently conducted the search and selected the studies according to the pre-specified clinical questions. CONTENT: Elderly patients with COVID-19 have peculiar characteristics. They may have atypical clinical presentation, with no fever and delirium or neurological manifestations as the most common signs, with potential delayed diagnosis and increased risk of death. The reported fatality rates among elderly patients with COVID-19 are extremely high. Several factors, including comorbidities, atypical presentation, and exclusion from ICU care contribute to this excess of mortality. Age alone is frequently used as key factor to exclude elderly from intensive care, but there is evidence that frailty instead of age better predicts the risk of poor outcome in this category. Durability of vaccine efficacy in the elderly remains debated and need for the third booster dose is becoming more and more evident. Finally, efforts to care for elderly who survived after acute COVID-19 should be implemented, considering the high rates of long COVID sequelae and the risk of longitudinal functional and cognitive decline. IMPLICATIONS: We hereby highlighted peculiar aspects of COVID-19 in elderly patients and factors contributing to high risk of poor outcome in this category. We also illuminated gaps in current evidence suggesting future research directions and underlining the need of further studies about the optimal management of elderly patients with COVID-19. adopted by governments and vaccine access and data need to be continually updated according to 105 spread of variants of concern (VOC) all over the world. (12/3293) in younger adults [11] . The occurrence of delirium in COVID-19 elderly patients has 116 been associated with a mortality of 48.4% [11] . Other atypical presentations may include falls, 117 generalized weakness, diminished food intake, changes in behavior, malaise and functional decline 118 [12] . 119 The accurate screening for typical and atypical symptoms of COVID-19 in elderly patients is 120 crucial to avoid diagnostic errors both in the Emergency Department and in special contexts such as 121 NHs or LTCFs [13] ; the under-reporting of symptoms in such structures contributes to a delayed 122 diagnosis with consequent spreading of the virus [13] . 123 A meta-analysis including more than 600.000 subjects showed that mortality changes across age 124 categories, ranging from 9.5% (8073/ 85.358) in patients of 60- There is general consensus that elderly represent a high-risk group which should be offered 202 vaccination with priority. However, compared to younger individuals, antibody response following 203 vaccination is generally lower because of a gradual deterioration of the immune system with age 204 and neutralizing antibody immune response following vaccination declines more precipitously in 205 elderly subjects [58] . Thus, the following unmet needs exist about vaccination in elderly subjects: 206 2) durability of immune response after booster dose of vaccine; 208 With regards to the efficacy of vaccination in elderly patients, contrasting data emerged from the 210 literature (Table 3) • Limited access to treatments (remdesivir, immunosuppressants). • Risk of decompensated underlying disease after start of treatments (e.g. steroids in patients with diabetes mellitus). Association of frailty with mortality in older Frailty is associated with in-hospital mortality in older hospitalised COVID-19 patients in the Netherlands: the COVID-OLD study Clinical features and outcomes of COVID-399 19 in older adults: a systematic review and meta-analysis Frailty 401 Assessment in the Emergency Department for Risk Stratification of COVID-19 Patients Epidemiology of COVID-19 in older 404 persons Clinical characteristics of COVID-19 in older adults. A retrospective study in long-term 407 nursing homes in Catalonia COVID-19: a 409 retrospective cohort study with focus on the over-80s and hospital-onset disease The role of frailty on patients 80 years of age or older with Coronavirus Disease 2019 (COVID-19) Remdesivir (Veklury®) Prescribing Information Effect of high-titer 477 convalescent plasma on progression to severe respiratory failure or death in hospitalized 478 patients with COVID-19 pneumonia: a randomized clinical trial Early high-481 titer plasma therapy to prevent severe Covid-19 in older adults Efficacy of 484 bamlanivimab/etesevimab and casirivimab/imdevimab in preventing progression to severe COVID-19 and role of variants of concern The Omicron 487 variant is highly resistant against antibody-mediated neutralization: implications for control 488 of the COVID-19 pandemic Dexamethasone in hospitalized patients with Covid-19 Phase 3 safety 524 and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine Efficacy and safety of 527 the mRNA-1273 SARS-CoV-2 vaccine Safety and 529 immunogenicity of two RNA-based Covid-19 vaccine candidates Safety 532 and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost 536 regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 537 2/3 trial Effectiveness of mRNA COVID-19 vaccines in preventing SARS-CoV-2 infections and 540 COVID-19 hospitalisations and deaths in elderly long-term care facility residents, Spain, 541 weeks Age-related 543 immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2 mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS CoV-2 Omicron variant 6-month consequences of COVID-552 19 in patients discharged from hospital: a cohort study Symptoms and health outcomes 554 among survivors of COVID-19 infection 1 year after discharge from hospitals in Wuhan Prevalence and predictors of 557 persistence of COVID-19 symptoms in older adults: a single-center study Post-infection cognitive 560 impairments in a cohort of elderly patients with COVID-19